Mosaic Therapeutics has closed its $28 million series A funding round and appointed former Novartis Oncology SVP Brian Gladsden as CEO.
The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies.
The funds will also support recruitment efforts, building the company’s senior leadership, experimental biology, and computational teams.
Gladsden commented: “I believe that Mosaic is ideally positioned to resolve the complexity of cancer, to discover and develop targeted therapies that address areas of high unmet need. The people, platform, connection to a world-leading genomics research institute, and strong investor partnerships are truly best in class.”
Mosaic uses computational methods, combining mining of large datasets with experimental approaches to identify and develop novel targeted therapies. The company’s platform applies research from co-founder Dr Mathew Garnett’s Translational Cancer Genomics Laboratory at the Wellcome Sanger Institute.
Dr Garnett said: “Mosaic is ready to lead the next wave of treatments for cancer, through the discovery of effective targeted therapies in molecularly-defined patients. With high calibre investors, an experienced CEO, and solid scientific foundations, we’re building an exceptional team to deliver on our vision to develop safer and more effective medicines.”
Mosaic is the most recent spin-out company from the Wellcome Sanger Institute, a world leader in genome research.
